"The decision is incomprehensible"
The European Medicines Agency (EMA) has recommended the refusal of the marketing authorization for the novel Alzheimer’s drug “Lecanemab” (brand name:…
MethodForum Witten
Background
The complexity of the phenomenon of dementia poses challenges for science and society. In addition to differentiated basic research and a variety of clinical…
back to overview
REALISE
General
The early detection of Alzheimer's disease using biomarkers is a prerequisite for the use of new antibody therapies in the treatment of the disease, which are…
Fahsold, Roes, Holle, & Kuliga (2023). Methods for the involvement of people living with dementia in research focused on the built environment: a protocol for a scoping review, BMJ Open, 13(8),…
Laporte Uribe, F., Löloff, J., Abi Jumaa, J., Wirsching, M., Votruba, N., Dadaczynski, K., Fischer, F., Tembele, R., & Community Hub on Global Mental Health. (2024). Stellungnahme zu den…
SMA appears to be preceded by abnormalities in embryonic development that have not yet been recognized and could hold approaches for therapy.
SMA appears to be preceded by abnormalities in embryonic…
European Medicines Agency recommends refusal of marketing authorization of novel Alzheimer’s drug
The European Medicines Agency (EMA) has recommended the refusal of the marketing authorisation…
Welcome to our website, here you can inform yourself basically cookie-free.
We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.
